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Abstract: Embryonal tumors of the nervous system are the leading cause of childhood 
cancer-related morbidity and mortality. Medulloblastoma, supratentorial primitive 
neuroectodermal tumors, atypical teratoid/rhabdoid tumor and neuroblastoma account for 
more than 20% of childhood malignancies and typify the current neural embryonal tumor 
model in pediatric oncology. Mechanisms driving the formation of these tumors point 
towards impaired differentiation of neuronal and neuron-associated cells during the 
development of the nervous system as an important factor. The importance of microRNAs 
(miRNAs) for proper embryonic cell function has been confirmed and their aberrant 
expressions have been linked to tumor development. The role of miRNAs in controlling 
essential regulators of key pathways implicated in tumor development makes their use in 
diagnostics a powerful tool to be used for early detection of cancer, risk assessment and 
prognosis, as well as for the design of innovative therapeutic strategies. In this review we 
focus on the significance of miRNAs involved in the biology of embryonal neural tumors, 
delineate their clinical significance and discuss their potential as a novel therapeutic target. 
Keywords: embryonal tumors; microRNAs; medulloblastoma; sPNET; AT/RT; 
neuroblastoma 
 
1. Introduction 
Embryonal tumors refer to a broad heterogeneous group of childhood malignancies that account for 
approximately 30% of childhood malignancies, including neuronal tumors of the central and peripheral 
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nervous system, in addition to other rare subtypes, such as rhabdomyosarcomas, Wilms’ tumor, and 
retinoblastoma [1]. Advances in cancer biology research have increasingly linked pediatric neoplasms 
with disordered mechanisms of normal development, supporting the model of embryonal tumorigenesis, 
both processes involve self-renewal and precisely coordinated proliferation, differentiation and cell 
migration [2]. The significances of miRNA-mediated regulation of gene expression during early 
embryogenesis and those that were linked to tumorigenesis have been established in human embryonal 
stem cells [3–21]. Based on these sightings, specific miRNA genes responsible for the control of 
embryonal stem cell proliferation and differentiation have been identified, which were also found to 
contribute to the initiation and progression of cancer stem cells [22–26]. Although the role of miRNA 
function in embryonal tumor development is still not completely understood, it is becoming clear that 
miRNAs are essential regulators of many of the key pathways implicated in the pathogenesis and 
progression of pediatric nervous system tumors [27]. This review focuses on the current understanding 
of the role miRNAs play in embryonal tumor development and progression, and will discuss their 
potential as new therapeutic targets. 
2. Embryonal Tumors of the Central and Peripheral Nervous System 
Embryonal tumors differ fundamentally from adult onset cancers, both in their cell biology and 
their tissue environment. They develop and manifest early in childhood and are usually characterized 
by a high rate of mortality and treatment-related morbidity [28]. Embryonal CNS tumors are a 
collection of biologically heterogeneous lesions that share the tendency to disseminate throughout the 
nervous system via cerebrospinal fluid (CSF). Embryonal CNS tumors include medulloblastoma  
(a malignant invasive tumor of the cerebellum), CNS primitive neuroectodermal tumors (a 
heterogeneous group of tumors arising in the cerebral hemispheres, brain stem or spinal cord), and 
atypical teratoid/rhabdoid tumors (AT/RT; a highly malignant CNS tumor predominantly manifesting 
in young children) [29]. Neuroblastoma (NB)—the most common extra-cranial embryonal tumor of 
childhood—arises in the sympathetic nervous system.  
3. microRNAs 
miRNAs are small non-coding RNAs that act as expression regulators of genes involved in 
fundamental cellular processes, such as development, differentiation, proliferation, survival and death [30]. 
Over the past few years, specific miRNAs have been reported to be implicated in various human 
cancers including brain tumors [9–21]. miRNAs were linked to tumorigenesis due to the fact that 50% 
of the miRNAs genes are located at genomic sites associated with cancer-specific chromosomal 
rearrangements as well as due to the proximity of their genes to chromosomal breakpoints [31,32].  
It has been found that miRNAs have the ability, in the context of human cancer, to behave like 
oncogenes or tumor suppressors, a finding which has important implications for cancer etiology and 
diagnosis [33–35]. Both losses and gains of miRNA functions through deletions, amplifications and 
mutations in miRNA loci or epigenetic silencing can contribute to cancer development [36].  
The frequent aberrant expression and functional implication of miRNAs in human cancers have lifted 
these small cellular components to the ranks of preferred drug targets that operate by a new mechanism 
of action. 
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4. miRNAs in Embryonic Cell Function and Tumor Development 
Increasing evidence suggests that embryogenesis and tumorigenesis display common characteristics. 
Both processes involve self-renewal and proliferation, differentiation and cell migration. Based on 
these parallels, researchers have begun to examine the role of miRNAs in neural precursor 
development and cell fate determination in order to determine whether brain developmental pathways 
are linked to brain tumor etiology [37]. Numerous publications demonstrate the importance of the 
developmental effects that are related to the miRNA-mediated regulation of gene expression during 
early embryogenesis in different species including C. elegans, Drosophila, Zebrafish and mice [38–47]. 
In humans, experimental data shows that miRNAs control the fate of human ESCs during early 
development [39,48–54]. Human ESCs for example, express a unique microRNAs (miR-200c, 368, 
154*, 371, 372, 373*, 373) [42] that might serve as molecular markers for the undifferentiated stem 
cells in early embryonic stage. The importance of miRNAs in the development of the mammalian 
nervous system was demonstrated in mouse mutants lacking the activity of Dicer, the type III RNAse 
that is necessary for miRNA biogenesis, which die at embryonic day 7, reviewed in [55]. Using zebrafish 
as a model, researchers discovered that specific miRNAs such as miR-92b, miR-124, miR-222,  
miR-218a, miR-26 and miR-29, miR-9 are expressed differentially between neural precursors and stem 
cells [56,57]. In differentiating embryonic stem cells of mammals, miRNAs that are specifically 
expressed or enriched in brain tissues, such as let-7a, miR-218, and miR-125, miR-200a, miR-200b, 
miR-429, miR138 and miR-141 with miR-124 and miR-9, were found to increase sharply in 
abundance during the transition from neuronal precursors to neurons [41,44,58–67]. Studying the 
expression pattern of miRNAs during mammalian brain development, Kim et al. [68] identified eight 
miRNAs (miR-103, -124a, -128, -323, -326, -329, -344, -192-2) to be temporally expressed in the rat 
cortex and cerebellum during neural differentiation and development [69]. In another study, using 
human embryonic cells that differentiate into neurons upon retinoic acid treatment, Sempere et al. 
showed that miR-9/9, -103-1, -124a, -124b, -128, -135, -156, -218 were co-ordinately induced during 
the neural differentiation process [60]. Some of these miRNAs are the same as the candidates Kim and 
colleagues showed to be developmentally regulated in rat brain corticogenesis, indicating important 
roles for these miRNAs in neuronal cell fate specification and differentiation. Remarkably some of 
these miRNAs were reported to be also active in neuron-developmental disorders [70]. 
The notion that cancer is fuelled by self-renewing stem cells is gaining prominence, and so is the 
idea that miRNA can direct cell fate. Yu F. et al. recently brought the two fields together by showing 
that a single miRNA molecule “miRNA let-7” can regulate stemness in breast cancer cells [22]. The 
important role of stem cells both in tissue and cancer development has driven much of the research 
into neural cancer stem cell biology. This research recently led to the identification of specific miRNA 
genes responsible for ESCs proliferation and differentiation and for the initiation and progression of 
cancer stem cells [22–26]. Silber et al. reported that miR-124 and miR-137 induce differentiation of 
neural stem cells and glioblastoma stem cells [25]. Desanomi et al. reported that miR-34 deficiency is 
involved in the self-renewal and survival of cancer stem cells and in cancer cells lacking functional 
p53, restoration of miR-34 was able to re-establish the tumor suppressing signaling pathway [26]. 
Amazingly, specific miRNAs such as miR-302 were recently found to be capable of reprogramming 
the cancer cells back into a pluriopotent embryonic stem cell-like state, which then could be induced 
Molecules 2014, 19 5824 
 
 
into tissue-specific mature cells [71]. Together these reports suggest that miRNA expression is vital  
for normal as well as abnormal ECS development that can lead to cancer stem cell initiation,  
reviewed in [26]. 
Cancer stem cells have been identified, isolated and characterized recently in embryonal neural 
malignancies including MB [72–76]. With the knowledge that MB harbors cancer-initiating cells with 
stem cell properties, scientists are making a great effort to understand the involvement of aberrantly 
expressed miRNAs in embryonal cancer stem cells and to elucidate the mechanisms, which distinguish 
these cells from normal stem cells. Functional studies on miRNAs within the cancer stem cells of MB 
will be crucial for elucidating the mechanisms behind oncogenesis in these deadly malignancies.  
The gained insight might reveal novel therapeutic targets, whose inhibition could impact the  
cancer-initiating cells and thus greatly reduce the risk of cancer relapse. 
5. Role of miRNAs in Embryonal Neuronal Tumors 
5.1. Medulloblastoma 
MB is the most common malignant tumor of the central nervous system and represents more than 
20% of all pediatric brain tumors [77]. MB is an invasive embryonal tumor of the cerebellum with an 
inherent tendency to metastasize via the subarachnoidal space [29]. Five histological varieties are 
recognized in the 2007 WHO classification: classic, anaplastic, large cell anaplastic, desmoplastic/nodular 
variant and MB with extensive nodularity [78]. Associations have been made between histopathological 
subtype and clinical outcomes. Patients with classical tumors tend to have average clinical outcomes, 
while desmoplastic/nodular MBs are associated with improved survival [78,79]. In contrast, large cell 
and anaplastic histologies predict shorter survival [79,80]. Several groups around the world have 
demonstrated that MB is not one disease but comprises a collection of distinct molecular subgroups. 
The current consensus is that there are four core subgroups, which should be termed WNT, SHH, 
Group 3 and Group 4 [81–84]. Kool and colleagues performed recently a meta-analysis of all 
molecular and clinical data of 550 MBs brought together from seven independent studies [85]. All 
cases were analyzed by gene expression profiling and for validation purposes they compared the 
results of this meta-analysis with another large (402) MB cohort for which subgroup information was 
obtained by immuno-histochemistry. The results from both cohorts were highly similar and confirmed 
the existence of the four MB subgroups and showed how distinct the molecular subtypes are with 
respect to their transcriptome [85]. Linking the subgroups to clinical follow-up data demonstrated  
that WNT and SHH carry favorable outcomes while group 3 and 4 are associated with poor  
prognosis [81,82,84,86,87]. The best outcome was found for WNT tumors. Interestingly, metastatic 
disease at diagnosis is also significantly associated with non-WNT/SHH tumors and most strongly 
with group 3 tumors [81,82,84]. 
5.1.1. miRNAs Aberrantly Expressed in MB 
Despite the intense investigation in the involvement of miRNAs in a variety of cancer types, 
knowledge of their role in MB pathogenesis has only recently started to build up. Pierson et al. [88] 
was the first to report the involvement of miRNA in MB. The authors found that the expression of 
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miR-124a—a brain enriched miRNA preferentially expressed in mature neurons and in external 
granule cells of the cerebellum, which were reported to be cells of origin of MBs [44,65,67]—is 
significantly decreased in MB cells compared to normal cerebellum. Similar decreases were also 
observed in other brain tumors [25,69]. Interestingly restoration of miR-124 function inhibits MB cell 
proliferation, suggesting that it may act as a suppressor of tumor growth. In a computational-based 
approach to predict miR-124 target genes, Pierson et al. discovered and validated cyclin dependent 
kinase 6 (CDK6) that was identified as an adverse prognostic marker in MB and solute carrier family 
16, member 1(SLC16A1) that may represent a novel therapeutic target for treatment of malignant  
MBs [89,90]. In a parallel but distinct study Ferretti et al. [27] used high-throughput screening to 
examine miRNA expression profiles in 34 patients with MB. Their investigation revealed a set of  
78 miRNAs with altered expression in MB, compared to normal adult and fetal cerebellar samples. 
Amazingly the authors identified a unique set of four up-regulated miRNAs (let-7g, miR-19a,  
miR-106b and miR-191) that are capable of distinguishing anaplastic variants from classic and/or 
desmoplastic MBs. Moreover, the authors found a number of developmentally regulated miRNAs that 
maintained levels of expression in MB similar to those observed in fetal cerebellum, supporting the 
notion that MBs exhibit some embryonic features. In MB samples they observed for example impaired 
expression of several neuronal miRNAs known to be expressed during neuronal development such as 
(miR-9 and miR-125a, miR-128a, 128b and miR-181b) suggesting that some of these miRNAs might 
be involved in MB tumorigenesis [91]. Notably all of these miRNAs with altered expressions were 
identified before in glioblastomas [92], suggesting a common role for these miRNAs in the etiology of 
malignant brain tumors. The authors selected miR-9 and miR-125a, as down-regulated neuronal 
candidates, for functional studies. Ectopic over-expression of miR-9 or miR-125a decreased 
proliferation, augmented apoptosis, and promoted arrest of MB tumor growth suggesting a role for 
both miRNAs as tumor suppressors [93]. These miRNAs mediated their effects through targeting of 
the pro-proliferative truncated isoform of the neurotrophin receptor TrkC, which is up-regulated in MB 
cells. Such findings are in line with those observed in neuroblastomas [91,94]. Consistently, other 
miRNAs in pediatric brain tumors including MB, such as miR-216, miR-135b, miR-217, miR-592, 
miR-340 were found to be over-expressed, whereas miR-92b, miR-23a, miR-27a, miR-146b, miR-22) 
were found to be underexpressed compared to normal brain tissues [95]. 
In addition to their role in promoting the development of primary tumors, miRNAs have also been 
implicated in the metastatic dissemination of tumor cells and alterations in miRNA function can 
influence metastatic potential [96,97]. Among several pro-metastatic miRNAs, miR-21 is up-regulated 
in a variety of solid tumors, including glioblastoma, breast, lung, colon, prostate, pancreas and stomach 
cancers [98] and has been causally linked to cell migration of several cancer cell lines [99]. We 
recently reported the aberrant expression of miR-21 in MB cells and showed that miR-21 regulated the 
expression of multiple target proteins associated with tumor dissemination, many of which are 
implicated in MB biology [100]. Importantly, repression of miR-21 decreased MB cell migration  
in vitro, possibly due to diminished repression of the tumor suppressor PDCD4. Thus, miR-21 could 
function as a pro-metastatic miRNA in MB and therefore raising the possibility that pharmaceutical 
strategies directed against miR-21 could improve the curability of selected MBs (Tables 1 and 2). 
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Table 1. Frequently deregulated miRNAs in neuronal embryonal tumors. 
Tumor 
miRNA  
regulation 
Validated or 
putative targets 
Potential function References 
MB 
Reviewed 
in [101–
104] 
miR-17/92 
Up 
TSP-1, Bmi-1, PTEN, 
PP2A 
Enhances proliferation, angiogenesis and 
confers growth advantage to MBs 
[90,105,106] 
Let-7 
Down 
RAS 
STAT3 
Disregulation leads to a less differentiated 
cellular state 
[107,108] 
miR-199b-5p 
Down 
HES1 
Notch pathway 
ErbB2 
Inhibits tumor growth and metastasis. Its 
restoration blocks expression of several cancer 
stem-cell genes 
[109] 
miR-34a 
Down 
Notch ligand Delta-like 
1 (Dll1) 
Negatively regulates cell proliferation, and 
induces apoptosis and neural differentiation in 
MB cells 
[110] 
miR-214 
Up 
Gli1 Undefined [27] 
miR-125a 
Down 
t-TrkC 
Its restoration decreases proliferation, augments 
apoptosis, and promotes arrest of MB tumor cell 
growth. 
[107] 
miR-9 
Down 
REST/NRSF, Hes1 
Inhibits MB cell proliferation and promotes 
differentiation 
[107,111] 
miR-125b 
miR-324-5p 
miR-326 
Down 
PKM2, SMO, Notch 
Inhibits MB cell proliferation, and reduces the 
size and number of MB cell colonies 
[27,112] 
miR-124a 
Down 
CDK6, SLC16A1, 
REST, BAF34a, RB1, t-
TrkC 
Cell cycle regulation. Inhibits proliferation and 
induces apoptosis 
[25,65,88,113,
114] 
* (miR-30b and  
miR-30d) 
Up 
Undefined 
Both miRNAs are part 
of an amplicon 
containing the 
KHDRBS3 gene on 
8q24.22 in MB cell lines 
Undefined [115] 
miR-218 
Down 
EGFR, Bcl-2, B-catenin 
and MAPK9 
Iinduces apoptosis, inhibits MB tumor growth 
and invasiveness 
[116,117] 
* miR-31 and 
miR-153 
Down 
Undefined. however,  
miR-153 is found in 
high ErbB2 expressing 
MB 
Undefined [107,117] 
miR-106b 
Up 
p21 Cell cycle arrest [107,116] 
miR-128a 
miR-128b 
miR-181b 
Down 
Bmi-1 
Inhibits growth of MB cells. 
miR-128a, alters the intracellular redox state and 
promotes cellular senescence in MB cancer stem 
cells, which are thought to be resistant to 
therapy due to their low ROS states 
[91,118] 
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Table 1. Cont. 
Tumor 
miRNA  
regulation 
Validated or 
putative targets 
Potential function References 
MB 
Reviewed 
in [101–
104] 
miR-21 
Up 
PDCD4. 
Pro-metastatic miRNA in MB. Involved 
in mitotic signaling, cell cycle, cell 
migration 
[100] 
miR-183~96~182 
cluster 
Up 
Undefined, however knockdown 
of the full miR-183~96~182 
cluster results in enrichment of 
genes associated with apoptosis 
and dysregulation of the 
PI3K/AKT/mTOR signaling axis 
Regulates multiple biological programs 
that converge to support the 
maintenance and metastatic potential of 
MB 
[119] 
* miR-216,  
miR-135b, miR-217, 
miR-592, miR-340 
Up 
Undefined Undefined [95] 
* miR-92b, miR-23a, 
miR-27a, miR-146b, 
miR-22 
Down 
Undefined Undefined [95] 
miR-148a. 
Up. 
Undefined Undefined [120] 
sPNET 
[103] 
* miR-517c miR- 
520g 
Up 
Undefined Undefined [121] 
* miR-19a, miR-
106b and miR-19 
Up 
Undefined Undefined [107] 
AT/RT 
miR-9 
Down 
Undefined Undefined [107,111] 
miR-517c, miR-520g 
Up 
miR-517c WNT/JNK signaling 
miR-520g ABCG2. 
Undefined [121,122] 
miR-221, miR-222 
Up 
p27Kip1 
Promotes proliferation through cell 
cycle progression in AT/RT cells 
[123] 
* miR-520b, miR-
629, miR-498, miR-
373 
Up 
Undefined Undefined [95] 
* miR-140, let-7b,  
miR-139, miR-153, 
miR-376b 
Down 
Undefined Undefined [95] 
let-7 miRNA family 
Down 
HMGA2 
Suppresses proliferation and colony 
formation and abolishes the invasive 
potential 
[124] 
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Table 1. Cont. 
Tumor 
miRNA  
regulation 
Validated or 
putative targets 
Potential function References 
NB 
Adapted 
from 
[102] 
miR-17-92 
Up 
DKK3, CDKN1A, BIM, 
ER-α, MEF2D 
Increases proliferation, decreases apoptosis 
and inhibits TGF-β signaling. miR-17-5p 
inhibition abolish growth of therapy-
resistant NB in vitro as well as in vivo 
[125–131] 
miR-124 
Undefined 
AHR Inhibits apoptosis and differentiation [127–130]  
miR-181 
Up 
ATM Undefined [125] 
miR-21 
Up 
PTEN 
Promotes proliferation, and decreases 
sensitivity to chemotherapy 
[127–130]  
miR-380-5p 
Up 
P53 Decreases apoptosis [132] 
miR-15a 
Up 
RECK 
Promotes migration through the induction of 
MMP-9 expression 
[133] 
* miRNA-125a/b 
Induced 
upon treatment with 
RA 
Modulate expression 
of the TrkC 
neurotrophin receptor 
Undefined [94,134] 
miR-184 
Undefined 
Akt2 downstream 
effector of the pro-
survival pathway PI3K 
Pro-apoptotic effects. Mediates proliferation 
reduction and inhibition of tumor growth in 
an orthotopic murine model of NB 
[135] 
miR-128 
Undefined 
Reelin and DCX 
Mediates differentiation, reduces motility, 
invasiveness, and growth of NB cells 
[136] 
miR-34a 
miR-34c 
miR-410,487b 
Down 
E2F3, BCL2, CCND1, 
CDK4, 
MYCN, P53 
Inhibits proliferation and induces apoptosis 
Ectopic expression of miR-34a leads to cell-
cycle arrest in NB lines 
[127,134,135,137
–139] 
miR-542-5p 
Expressed in 
favorable NB, absent 
in unfavorable NB 
GRIN3A, SH3GLB2, 
SNIP 
Inhibits tumor growth, invasiveness and 
metastasis. 
[125,140] 
miR-628 
Expressed in 
favorable NB, absent 
in unfavorable NB 
Undefined Undefined [125,140] 
miR-let-7 
Down-regulated in 
NB with MYCN 
amplification 
MYCN 
Inhibits proliferation and induces 
differentiation. Altered expression of let-7 
leads to a less differentiated cellular state 
[141] 
miR-101 
Down-regulated in  
NB with MYCN 
amplification 
MYCN Inhibits proliferation and clonogenic growth [141] 
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Table 1. Cont. 
Tumor 
miRNA  
regulation 
Validated or 
putative targets 
Potential function References 
NB 
Adapted 
from 
[102] 
miR-885-5p 
Down 
CDK2, MCM5 Inhibits cell cycle progression and survival [142] 
miR-27b 
Down 
PPARγ Inhibits tumor growth [143] 
miR-138 
Down 
Undefined Decreases viability and growth [144] 
miR-137 
Down 
KDM1A Inhibits proliferation and induces apoptosis [145] 
miR-204 
Down 
BCL2, NTRK2. 
Increases sensitivity to cisplatin and 
etoposide 
[146,147] 
miR-190 
Down in aggressive 
NB with unknown 
mechanism 
NEUROD1 
Inhibits TrkB pathwayand aggressive 
phenotypes. 
[147] 
miR-10a/b 
Down 
NCOR2 
miR-10a/b 
Induces differentiation [148] 
miR-335 
Down 
ROCK1, MAPK1, 
LRG1 
Inhibits migration and invasion [149,150] 
 
miR-363 
Down 
Undefined Inhibits invasiveness and metastasis [149] 
miR-9 
Down 
MMP-14 
Inhibits the invasion, metastasis, and 
angiogenesis 
[151] 
miR-145 
Down 
HIF-2α Inhibits NB cell growth, invasion, metastasis 
and angiogenesis 
[152] 
* miR-140 let-7b 
miR-139 
miR-153 miR-376b 
Down 
Undefined Undefined [95] 
let-7a3/let-7b 
miRNA 
Down 
HMGA2 Undefined [124] 
* Poorly characterized miRNA/s in the specific tumor setting.  
Table 2. Clinical relevance of miRNAs in NB [102,125,130,131,153–159]. 
miRNAs up/down regulated in 
high-risk NB 
miRNAs  
up-regulated in 
metastatic NB 
miRNAs up/down regulated 
as a marker for poor 
survival of NB 
miRNAs up/down 
regulated in 
unfavorable NB 
↑miR-18b, ↑miR-20a, ↑miR-22, 
↑miR-92a, ↑miR-181a, ↑miR-181a-2, 
↑miR-203, ↑miR-373, ↑miR-383, 
↑miR-422a, ↑miR-876-5p, 
↑miR-1208, ↑miR-1285, ↑miR-1290, 
and ↑miR-129 and ↓miR-30b, 
miR-24,  
miR-92b,  
miR-99b,  
miR-129-3p, 
miR-130b,  
miR-342-3p, 
↑miR-380-5p, ↑miR-17-92 
cluster, including ↑miR-17-5p, 
↑miR-18a, ↑miR-19a,  
↑miR-20a and ↑miR-92 and 
↓miR-542-5p, ↓miR-497  
miR-18a and miR-19a 
↑miR-181, ↑miR-21, 
↓miR-542-5p,  
↓miR-628,  
↓miR-410,  
↓miR-487b,  
↓miR-30c, ↓miR-149, 
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Table 2. Cont. 
miRNAs up/down regulated in 
high-risk NB 
miRNAs  
up-regulated in 
metastatic NB 
miRNAs up/down regulated 
as a marker for poor 
survival of NB 
miRNAs up/down 
regulated in 
unfavorable NB 
↓miR-146a, ↓miR-190, ↓miR-204, 
↓miR-215, ↓miR-299-5p, ↓miR-362, 
↓miR-382, ↓miR-411, ↓miR-424, 
↓miR-425, ↓miR-487b, ↓miR-532, 
↓miR-629, ↓miR-656, ↓miR-660, 
↓miR-668, ↓miR-744, ↓miR-758, 
↓miR-873, ↓miR-885-5p, and  
↓miR-1197, miR-30c, ↓miR-149, 
↓miR-195, miR-324-5p and  
↓miR-331 
miR-345,  
miR-483-3p, 
and  
miR-486-5p. 
miR-17-92 
(correlates with increased 
event-free survival and 
favorable disease outcome). 
↑miR-184 (increases overall 
survival). 
↑miR-204 (associated with a 
favourable clinical outcome 
and increases sensitivity to 
chemotherapy). 
↓miR-195,  
↓miR-324-5p ↓and 
miR-331 
↑: Upregulated, ↓: Downregulated.  
5.1.2. MB Subgroups Have Distinct miRNA Profiles 
Genome-wide miRNA expression studies have revealed close associations between miRNA clusters 
and MB tumor subtypes as well as clinical subgroups [90,107,119,160]. Additionally, miRNA 
profiling studies demonstrated that it is possible by miRNA signatures to discriminate MB histological 
subtypes. While miR-21, a known oncomir [161], was up-regulated across all MB subgroups relative 
to normal cerebellum, Northcott and colleagues reported that miR-17/92 cluster was found to be 
significantly up-regulated in SHH-driven MB [90,162]. The group concluded that miR-17/92 is a 
positive effector of SHH-mediated proliferation and that aberrant expression/amplification of this 
miRNA confers a growth advantage in a specific subpopulation of MBs. Their results were confirmed 
by the discovery that miR-17/92 promoted proliferation of MB cell lines in vitro and contributed to the 
development of MB in vivo [90,162]. In other studies microRNAs encoded by the miR-17/92 and  
miR-106b-25 clusters were found to be over-expressed specifically in human and mouse SHH  
MBs [107,163]. Consistent with its high expression in SHH MB, enforced expression of the miR-17/92 
cluster, together with mutation of Ptch1+/−, accelerates the onset and penetrance of SHH MB [162]. 
Tumor progression can be inhibited by using miRNA inhibitors that target the seed sequence of  
miR-17/20 and miR-19a/b in SHH MB cells in vitro and in animals bearing flank or cortical SHH MB 
allografts [164]. These data suggest that miRNAs inhibitors targeting the miR-17/92 cluster family 
could be therapeutically useful in SHH MB and other cancers that over-express members of this 
cluster family [165]. Weeraratne and colleagues have reported that increased expression of the  
miR-183~96~182 cluster characterizes non-SHH MBs. This cluster of miRNAs was found to be 
associated with MB subgroups characterized by genetic amplification of MYC [119]. Remarkably, 
miR-182 is known to promote metastasis, a hallmark of aggressive MBs [166]. Three other 
microRNAs were found to be differentially regulated in MYC-over-expressing MBs compared to MBs 
in which MYC is not over-expressed [107]. However, whether these microRNAs are directly regulated 
by MYC is yet unknown, reviewed in [165]. In another publication Cho et al. discovered a previously 
unidentified molecular subgroup, characterized genetically by MYC copy number gains and 
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transcriptionally by enrichment of photoreceptor pathways and increased miR-183-96-182 expression. 
This newly discovered subgroup is associated with significantly lower rates of event-free and overall 
survivals [167]. For the WNT MB subgroup, Gokhale et al. reported a distinctive microRNA signature 
associated with the WNT signaling pathway. In their study miR-193a, miR-224/miR-452 cluster,  
miR-182/miR-183/miR-96 cluster, and miR-148a having potential tumor/metastasis suppressive 
activity were found to be over-expressed in the WNT signaling associated MB [120]. 
In summary, the altered miRNA expression signatures in distinct MB subtypes highlight the 
functional significance of these novel oncogenic molecules in MB tumor formation and progression. 
Such discoveries not only provide new insights into the molecular pathogenesis of MB tumors, but 
also raise hopes for translating the increasing knowledge of miRNA expression and functions into 
diagnosis, prognostication and therapy. 
5.2. Supratentorial Primitive Neuroectodermal Tumors 
The supratentorial primitive neuroectodermal tumors (sPNET), which represent 3%–7% of all 
pediatric brain tumors, are a group of highly malignant lesions primarily affecting young children. 
Although these tumors are histologically indistinguishable from infratentorial MB, they often respond 
poorly to MB-specific therapy [168]. Indeed, the very few existing molecular genetic studies indicate 
that sPNET have cytogenetic profiles that are different from those of MBs, thus pointing to unique 
biological derivation for the supratentorial PNET. sPNET are a heterogeneous group characterized by 
primitive neuroepithelial cells with variable neuronal, glial, or ependymal differentiation [121]. Unlike 
AT/RT, which are defined by INI1 gene alterations [169], sPNET may pose significant diagnostic 
challenges due to lack of characteristic genetic or immunohistochemical markers [121]. Due to the 
shortage of these tumors, comprehensive genetic studies of a substantial number of sPNETs have not 
yet been undertaken. Therefore, the lack of insight into the molecular pathogenesis of sPNET has 
become a major obstacle toward development of disease-specific models and treatments. 
miRNAs Aberrantly Expressed in sPNET 
Owing to the rarity of these tumors and disagreement about their histopathological diagnoses, very 
little is known about the molecular characteristics of sPNET. Additionally, the role of miRNAs in 
sPNET was not yet established until recently [170]. The chromosome 19 microRNA cluster (C19MC) 
is the largest human microRNA gene cluster described so far. This miRNA cluster spans 100 kb at 
human chromosome 19q13.42 and comprises 54 tandemly repeated miRNA genes [171]. Amplification 
of a miRNA cluster at 19q13.42 has been identified recently as a genetic hallmark of sPNET, and it is 
considered a unifying molecular diagnostic marker for these tumors [121,171,172]. Very recently  
Li et al. established that amplification of C19MC was present in aggressive sPNET tumor cells [121]. 
They showed that miR-517c and/or 520 g in the C19MC group could stimulate growth and prevent 
development of normal human neural stem cells into more mature types of brain cells. They also 
reported that constitutive expression of miR-517c or 520 g promotes in vitro and in vivo oncogenicity. 
Furthermore, the group showed that C19MC miRNA oncogenes may confer aggressive tumor 
phenotype by altering signaling pathways that regulate normal neural stem cell growth. Their data 
describe for the first time miR-517c and 520 g as oncogenes in sPNET and highlight C19MC as an 
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attractive candidate biomarker and therapeutic target for aggressive pediatric brain tumors. 
Interestingly, Kleinman and colleagues reported recently that embryonal tumors with multilayered 
rosettes (ETMR), an aggressive pediatric brain tumors of sPNET variant that originate from early 
neural stem cell precursors, are characterized by a recurrent fusion that joins the promoter of a gene 
with brain-specific expression (TTYH1) to C19MC. This fusion event, which is unique to ETMRs, 
drives high levels of expression of the miRNA cluster in these tumors, reawakening a transcriptional 
program that is normally only active during the early stages of embryonic development [173,174]. 
Together these findings support the emerging theme that miRNAs are important determinants of 
sPNET embryonal tumor biology. 
5.3. Atypical Teratoid/Rhabdoid Tumors (AT/RT) 
AT/RT are rare but highly aggressive tumors that typically occur in infancy or early  
childhood [175,176]). Rhabdoid tumors predominantly arise in the kidney and brain, but they can also 
be found in a deep axial location, such as the neck or the paraspinal region [177]. Different forms of 
rhabdoid tumors can be similar in their aggressiveness, histological features, and loss of function of 
INI1/hSNF5 mapping on chromosome 22 [178,179]. From the clinical experience, infants and children 
with rhabdoid tumors respond very poorly to chemotherapy and radiotherapy [180–182], although this 
remarkable resistance to both cytostatic drugs and radiotherapy has not yet found convincing 
explanation at the molecular level. 
miRNAs Aberrantly Expressed in AT/RT 
To find new potential therapeutic targets for the treatment of AT/RT, Sredni and colleagues [123] 
investigated differentially expressed miRNAs when comparing four AT/RT with six MB and  
normal brain samples. Within the top differentially expressed miRNAs, the deregulated expression of 
miR221/222 was demonstrated to inhibit the expression of the tumor suppressor and inhibitor of cell 
cycle p27Kip1. These results suggest that miR-221/222 over-expression might be one of the factors 
contributing to oncogenesis and progression of AT/RT through p27Kip1 down-regulation. The authors 
suggested that anti-miR221/222 therapy might be an option for the treatment of these very aggressive 
and unresponsive tumors. In a comprehensive study Birks et al. [95] compared miRNAs expression in 
pediatric brain tumors and normal tissue controls by microarray. Their result showed that miR-129, 
miR-142-5p, and miR-25 were differentially expressed in every pediatric brain tumor type compared to 
normal tissue controls. In AT/RT miR-520b, miR-629, miR-221, miR-498, miR-373* were up-regulated 
while miR-140, let-7b, miR-139, miR-153, miR-376b were under-expressed. Zhang et al. [124] have 
recently searched for novel genomic aberrations by investigating the copy number and expression 
alterations of let-7a3/let-7b miRNA and correlated these with expression of high-mobility group  
AT-hook 2 (HMGA2) oncoprotein, a target of let-7 miRNA family, in 18 AT/RT samples. Their 
analysis demonstrated that HMGA2 was highly over-expressed in 83.3% (15/18) of AT/RT tissues 
while let-7a3/let-7b miRNA copy number and expression were reduced. Restoration of let-7 miRNA 
or knockdown of HMGA2 expression significantly suppressed proliferation and colony formation and 
almost abolished the invasive potential of G401 Wilms’ tumor cell line. The authors suggested that 
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HMGA2 oncoprotein plays critical roles in the pathogenesis of AT/RT development and reconstitution 
of let-7 miRNA may provide a novel therapeutic strategy for the treatment of AT/RT patients. 
5.4. Neuroblastoma 
NB is the most common extra-cranial solid tumor in childhood, accounting for approximately 7%–10% 
of pediatric cancers and 15% of all cancer-related deaths in patients less than 15 years old [183–185]. 
NB is an extremely heterogeneous disease both biologically and clinically [183,184,186]. NB is 
thought to be an embryonal tumor that is derived from precursor cells of the peripheral (sympathetic) 
nervous system [2,187]. The tumor can arise anywhere along the sympathetic chain but is most 
frequently in the adrenal medulla and paraspinal ganglia [187,188] reviewed in [189]. The clinical 
outcome of NB can range from complete regression (mainly in infants) to rapid tumor progression and 
metastasis with poor prognosis [190]. Many genetic abnormalities have been identified in NB tumors, 
including amplification of the MYCN proto-oncogene (25%–33% of patients) and consistent areas of 
chromosomal deletion and rearrangement that result in loss of 1p36 (25%–35%), 11q23 (35%–45%), 
and 14q23 (16%–27%), as well as unbalanced gain of 17q22 (~50%). Many of these abnormalities are 
powerful prognostic markers and are highly related to clinical outcome. For example, NB tumors 
which harbor 1p36 LOH and MYCN amplification are usually advanced-stage aggressive tumors that 
are frequently metastatic and generally respond poorly to chemotherapy/irradiation [183,184]. 
Amplified MYCN has been proposed as an example of the first clinical application of cellular 
oncogenes, and is now established as a powerful molecular parameter to determine patient prognosis, 
as well as a basis for patient stratification [183,191,192]. 
MicroRNAs Aberrantly Expressed in NB 
Aberrant regulation of miRNA expression has been implicated in the pathogenesis of NB (Tables 1 
and 3), and miRNA expression profiles have been correlated with prognosis, and cell differentiation, 
and apoptosis [193], suggesting that miRNAs could function as tumor suppressors or oncogenes in 
NB. Guo et al. compared miRNA expression patterns of primary and metastatic NB tumors and found 
significant changes of 54 miRNAs [153]. MiR-10b, miR-29a/b, miR-335, which are known to promote 
metastasis were up-regulated in metastatic NB tumors. In contrast, miR-7, miR-338-3p and the let-7 
family were three of the top 10 down-regulated miRNAs in the metastatic group. Interestingly, these 
miRNAs have been shown to play anti-metastatic roles in other tumors [194], and target gene analysis 
of these miRNAs revealed that many of these targets are related to metastasis. For instance, both 
caspase-8 and integrin beta1 are predicted targets of miR-29a and miR-29b, miRNAs known to 
promote metastasis in breast cancer [195] reviewed in [189]. While the MYCN protein is established 
as an important regulator of several miRNAs involved in NB tumorigenesis, tumor suppressor 
miRNAs have also been documented to repress MYCN expression and inhibit cell proliferation of 
MYCN-amplified NB cells [196]. Several studies published during the last 5 years have implicated 
MYCN in the regulation of the expression of several miRNAs, many of which have important roles in 
cancer progression. miRNA induction by MYCN is associated with a widespread repression of coding 
genes and disease-relevant pathways in NB cells, suggesting that miRNA-controlled regulation of 
certain groups of miRNAs may function as an additional mechanism of MYCN-induced oncogenicity. 
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Indeed, among the targets of MYCN-responsive miRNAs (mir-17/92 cluster, mir-9 and mir-421) there 
are tumor suppressors and genes involved in the metastatic process. Fontana and co-authors [197]  
and Schulte and colleagues [198], showed that miRNAs of the miR-17/92 cluster are over-expressed  
in NB tumors and cell lines with high MYCN expression. Other studies have confirmed direct  
binding of MYCN to the miR-17-92 promoter [154,199], as well as a positive correlation between 
expression of MYCN and members of the miR-17/92 cluster in NB primary tumors and/or cell  
lines [125,126,154,200–202]. On the other hand, miRNAs with tumor suppressor functions (mir-184 
and mir-542-5p) have been shown to be inversely correlated to MYCN expression [140,155,193,203]. 
In fact, miRNA repression seems to be the predominant consequence of MYCN activation, as high 
MYCN expression is associated with a global repression of miRNAs. Vice versa, miR-34a, miR-101 
and let-7 have been documented to target MYCN mRNA, resulting in reduced MYCN expression and 
decreased proliferation of MYCN-amplified NB cells [196]. 
Table 3. Biological and clinical relevance of miRNAs in MB. 
miRNAs associated with 
signaling pathways involved in 
MB classification/pathogenesis 
miRNAs associated with MB 
and neuronal stem cell biology 
miRNAs associated with 
metastasis in MB 
miRNAs associated with 
risk stratification/outcome 
prediction 
↓miR-125b, ↓miR-326, and 
↓miR-324–5p, ↑miR-214 and 
↓miR-92 (associates with SHH) 
[27] 
miR-17/92 (promotes neural stem 
cells development, modulating its 
cell-fate decision and are also 
involved in cancer stem cells and 
in MBs biology) [204] 
miR-21, miR-182 (promotes 
metastasis)miR-182 
contributes to leptomeningeal 
metastatic dissemination in 
non-SHH-MB [166] 
Tumor suppressor miR-31 
and miR-153  
(down-regulated in clinical 
high risk MB patients) 
[91,107] 
↑miR-183~96~182 (associates 
with genetic amplification of 
MYC in the most clinically 
aggressive MB subgroup) 
[119,166] 
miR-199b-5p (negatively 
regulates MB tumor stem-cell 
positive to CD133 antigen) [109] 
miR-193a, miR-224/miR-452 
cluster,, and miR-148a 
(potential metastasis 
suppressive activity) [160] 
Oncogene  
miR-183~96~182 (highly 
expressed in the most 
clinically aggressive MB 
subgroup) [119] 
↑miR-17-92 (correlates with 
SHH as well as c-MYC/MYCN 
activation in MB) [162] 
miR-125b, miR-324-5p, and 
miR-326 (regulate SHH signaling 
in cerebellar granule neuron 
precursors and MB cells) [27] 
miR-199-5p (confreres 
inhibition of MB metastasis) 
[109] 
Tumor suppressor miR-9 
(downregulation is a 
predictive marker for poor 
prognosis in MB) [111] 
miR-10b, ↑miR-135a,  
miR-135b, ↑miR-125b and 
↓miR-153 (associated with 
ErbB2 overexpressing MB 
tumors) [91,107] 
miR-7, miR-9, and ↓miR-124 
(associated with MB and 
Neuronal Differentiation) 
[103,104,111] 
 
Tumor suppressor  
miR-199-5p (low 
expression is a predictor for 
a poor-risk MB class) [109] 
↓miR-181b, miR-128a, and 
↓miR-128b (associated with  
c-MYC overexpressing MBs) 
[91,107] 
  
miR324-5p and miR326 
(promote progressive events 
in MBs) [27] 
↓miR-199b and ↓miR-326 
miR34a (associated with Notch 
Signaling pathway) [109] 
  
Tumor suppressor  
miR-128b miR-181b low 
expression (correlates with 
MB disease risk) [91,107] 
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MB classification/pathogenesis 
 
 
miRNAs associated with MB  
and neuronal stem cell biology 
miRNAs associated with 
metastasis in MB 
miRNAs associated with 
risk stratification/outcome 
prediction 
↑miR-193a, ↑miR-224/ 
↑miR-23b, ↑miR-365 and  
↑miR-148a (over-expressed in 
the WNT signaling associated 
MB) [120,160] 
    
↑miR-let7g, ↑miR-19a,  
↑miR-106b and ↑miR-
191distinguish MB differing in 
histotypes (anaplastic, classic 
and desmoplastic [107] 
    
↑: Upregulated, ↓: Downregulated.  
6. Role of miRNAs as Biomarkers 
With the increasing implication of miRNAs in cancer development and progression, significant 
efforts are underway to use miRNAs as novel biomarkers with clinical applications [205,206]. miRNA 
expression is dynamic: many miRNAs are deregulated in early stages of tumor development and  
up-regulated during cancer progression and could thus be of potential diagnostic utility [207,208]. 
miRNA expression profiling has been used to characterize embryonal and differentiated tissues of the 
nervous system [56], to discriminate cancer from normal tissue [97,161] and it can also be used to 
differentiate primary from metastatic brain tumors [209]. Moreover, miRNAs may be used as 
biomarkers to identify individuals with increased disease risk, as well as novel prognostic factors [210]. 
Of note miRNAs can also be detected circulating in several body fluids, including plasma, serum, 
cerebrospinal fluid, urine and saliva [211–214], reviewed in [215,216]. There are significant 
differences between the circulating miRNA expression profiles of healthy individuals and those of 
patients. Consequently, circulating miRNAs are likely to become a novel class of non-invasive and 
sensitive biomarkers [217]. To be classified as an ideal biomarker, it is crucial that miRNAs show 
satisfactory predictability and the ability to be inspected during onset, progression and/or regression of 
the disease. The ease of obtaining and detecting such biomarker from clinical samples is also 
important. In that regard, circulating miRNAs are particularly promising potential biomarkers in 
diagnosing diseases because they exhibit an unexpected stability in various body fluids [206,218]. 
Importantly, obtaining clinical samples that contain circulating miRNAs is a non-invasive and  
simple process. Moreover, the miRNAs can then easily be detected using quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR), an efficient and easy to apply technique. These 
advantages indicate that circulating miRNAs have the potential to be useful candidates for diagnosis 
and other clinical applications in human diseases. However, because of the small amount of circulating 
miRNAs, extracting miRNA from body fluids remains technically challenging and needs to be 
improved. Despite the limitations, the application value of circulating miRNAs in various diseases is 
gradually being uncovered, reviewed in [217]. In fact the use of circulating microRNAs as potential 
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biomarkers is a rapidly evolving field of study [206,219] and the number of recent publications has 
increased rapidly over the past two years. In the context of CNS diseases, several studies have 
demonstrated significant presence of certain miRNAs in CSF samples from patients with CNS 
lymphoma, glioma [214], metastatic brain cancers [213] and Alzheimer’s disease [220]. However,  
the true source of miRNAs in the body fluids and their exact secretory mechanism is relatively 
unknown [221]. A number of hypotheses have been put forward, such as that circulating miRNAs are 
present as a result of cell death and lysis or as a result of being actively secreted by cells [222]. The 
last hypothesis involves either encapsulation of miRNAs into microvesicles such as exosomes [223,224] 
or alternatively secreted as microvesicle-free (naked) miRNAs [225]. Tumor-derived exosomes 
containing miRNAs are generally considered pro-tumorigenic. Recent studies have shown that 
miRNAs contained in tumor-derived exosomes are able to transfer their oncogenic activity to recipient 
target cells and promote cancer stimulatory activities, such as proliferation, extracellular matrix 
remodeling, migration, invasion and angiogenesis, and contribute to the pre-metastatic niche formation 
for the promotion of metastasis, reviewed in [226]. This potential exchange of miRNAs is an exciting 
and novel dimension to the regulation of a cell’s phenotype [227] and is particularly important in 
cancers that have a propensity for dissemination such as embryonal tumors. 
7. Risk Stratification and Outcome Prediction 
7.1. Prediction of Clinical Outcome in MB 
Risk stratification and prognosis assessment have become a major concern in the era of 
personalised medicine. Gene expression profiling has reached a plateau in this regard, although recent 
miRNA studies show great promise [90,119,160] reviewed in [21]. Ferretti et al. identified specific 
miRNA expression patterns, which distinguish MB differing in histotypes (anaplastic, classic and 
desmoplastic) and in disease-risk stratification. The authors reported four miRNAs (miR-let7g,  
miR-19a, miR-106b and miR-191) that are significantly up-regulated in anaplastic versus desmoplastic 
MBs, miR-let7g and miR-106b were differentially expressed between desmoplastic and classic tumors 
while only miR-19a was up-regulated in anaplastic versus classic MBs [107]. Importantly their analysis 
identified both miR-31 and miR-153 as down-regulated in clinical high risk MB patients [91,101,107]. 
In another study Weeraratne and colleagues reported that increased expression of the miR-183~96~182 
cluster of miRNAs has been noted in the most clinically aggressive subgroup and associated with 
genetic amplification of MYC [119]. Our group recently identified miR-9 as a methylation-silenced 
tumor suppressor that could be a potential candidate predictive marker for poor prognosis of MB [111]. 
The investigation demonstrated that LC/A MB samples possess lower miR-9 expression compared to 
the other variants whereas miR-9 under-expression was associated with poor prognosis in 34 patient 
samples of MB. The lower overall survival probability of patients with low miR-9 expression that also 
tends to have a more severe pathological grade suggests a strong trend towards prognostic significance. 
Moreover, in line with previous reports high expression of the main miR-9 target gene (HES1) 
correlated significantly with lower overall survival in a distinct cohort of 129 MB samples [167]. 
Together these data indicate that low expression of miR-9 and the consequently increased expression 
of its target gene HES1 could be associated with worse MB clinical outcome. In addition, Garzia et al. 
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reported that the expression of miR-199-5p (that also targets HES1) is a robust predictor for a  
poor-risk class and correlates with metastatic spread in patients with MB [109]. In summary, although 
further verification is required to validate the role of miRNAs in MB risk stratification and outcome 
prediction, the above mentioned data imply that in the very near future miRNAs may have a wide 
clinical applicability as potential diagnostic and prognostic biomarkers for MB patients. 
7.2. Prediction of Clinical Outcome in NB 
Several miRNAs have been found to have links with the outcome of NB patients [134,228]. In 
searching for miRNA target signatures in advanced stage NBs, Guo et al. show that 54 different 
miRNAs are significantly altered in metastatic as opposed to primary NB tumors [153]. In another 
study by Pray and colleagues, miR-542-5p over-expression decreases the invasive potential of NB 
cells [140]. The authors demonstrated that lower expression of miR-542-5p is highly associated with 
poor patient survival, while ectopic over-expression of this miRNA decreases the invasive potential of 
NB cell lines in vitro, along with primary tumor growth and metastases in an orthotopic mouse 
xenograft model. In a parallel study Schulte et al. confirmed that miR-542-5p also discriminated 
between local and metastatic disease and was inversely correlated with MYCN amplification and 
event-free survival [155]. Chen et al. identified several miRNAs differentially expressed in different 
prognostic subtypes of NB. Usually, most of them are down-regulated, as result of MYCN amplification 
in NB high-risk subgroup. Combined with MYCN amplification, miRNAs down-regulation predicts  
a poor prognosis in NB patients [193]. In agreement with this trend Creevey et al. determined that 
miR-497 expression was significantly lower in high-risk MYCN amplified tumors and that low  
miR-497 expression was associated with worse event-free survival and overall survival in their  
cohort [229]. The group showed that miR-497 restoration in MYCN amplified NB cells increases NB 
apoptotic cell death in vitro. Another study showed high expression of MRHG1 was significantly 
associated with high-risk groups of NB, which was caused by dysregulation of miR-17, miR-18a,  
miR-19a, miR-20a and miR-92a [117]. The oncogenic activity of miR-18a and miR-19a was proven 
by Lovén et al. miR-18a and miR-19a have been found to target and repress the expression of estrogen 
receptor-alpha (ESR1) and high ESR1 expression correlates with increased event-free survival in NB 
patients and favorable disease outcome [154]. In preclinical studies Tivnan et al. showed that miR-184 
significantly reduces tumor growth and increases overall survival in an orthotopic murine model of  
NB [135]. Others demonstrated that miR-204 increases sensitivity of NB cells to cisplatin and is 
associated with a favourable clinical outcome [146]. Deep sequencing by Schulte et al. revealed 
differential expression of miRNAs in favorable versus unfavorable NB. Oncogenic miRNAs of the 
miR17/92 cluster and the miR-181 family were found to be over-expressed in unfavorable NBs. In 
contrast, the putative tumor suppressive miR-542-5p and miR-628 were expressed in favorable NBs 
and virtually absent in unfavorable NBs [125]. Predicting outcome of individual NB patients within 
risk groups remains challenging and established cytogenetic abnormalities such as MYCN amplification 
or segmental chromosomal abnormalities do not identify all patients with adverse outcome. 
Deregulation of miRNAs is associated with the development and progression of NB, hence in the next 
decade miRNAs are expected to have a significant effect on clinical oncology for the diagnosis and 
prognosis of NB, and may serve as novel targets for the treatment of high-risk NB patients. 
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8. Pros and Cons of the miRNAs as Biomarkers for Embryonal Neural Tumors 
If the ultimate expectation of miRNAs as biomarkers is to enhance the ability to manage the patient 
optimally, a key question to ask is whether miRNA biomarkers would significantly improve the 
diagnostic workup and eventually lead to positive targeted clinical outcome when compared to already 
in-use diagnostic standards. 
Four major risk stratification systems for NB patients are currently being used by combining 
various clinical, histopathological and molecular markers, such as established cytogenetic 
abnormalities, mainly chromosomal abnormalities and MYCN amplification. Accordingly, different 
therapeutic schemes exist ranging from wait-and-see approaches to intensive multimodal therapies. 
Although the currently used risk stratification systems are considered useful, patients receiving the 
same treatment can have markedly different clinical courses [230], and established cytogenetic 
abnormalities do not identify all patients with adverse outcome. On the contrary, molecular-based MB 
risk stratification is not yet in use in the clinics. Nevertheless a current consensus identifies the 
existence of four major subgroups of MB, with good prognosis for those with WNT tumors, 
intermediate prognosis for those with SHH and Group 4 tumors and poor prognosis for those  
with Group 3 tumors [87]. However, evidence suggests clinical heterogeneity within these core 
subgroups [86,167,231] and importantly the putative markers are still waiting to be validated in 
prospective clinical trials. 
Considering the limitations of current cancer conventional biomarkers, the use of miRNAs as tumor 
markers for diagnosis and prognosis has aroused intense research interests in particular after the 
outstanding advances in miRNA technologies, such as miRNA microarrays, specific quantitative PCR 
of miRNA, bead-based miRNA profiling, and antisense technologies. Advanced technologies not only 
help to identify the oncogenic and tumor suppressor potentials of miRNAs, but also assist in providing 
a more comprehensive understanding of their underlying mechanisms and pathways. miRNA 
microarrays can identify the expression of several hundreds miRNAs genes in the same sample at once 
while requiring only small amounts of total RNA. The widespread and comprehensive use of these 
high-throughput arrays has enabled the quantification of miRNA expression and the identification of 
miRNAs uniquely expressed within specific disease [205]. Moreover, profiling of miRNA expression 
patterns was shown to be more useful than the equivalent mRNA profiles [232]. As such, miRNA 
expression “signatures” are expected to offer serious potential markers for diagnosing and prognosing 
cancers of any provenance. However this does not go without restrictions. From clinical sensitivity and 
specificity point of view although it is suggested that miRNAs would provide increased sensitivity 
because miRNA profiles have been demonstrated to be pathognomonic, or tissue-specific; however, 
this does not necessarily translate into disease specificity [233]. The other restrictions that hinder the 
use of miRNAs as biomarkers include those inherently associated with conventional biomarkers. For 
example detection and quantification of an ideal marker should be simple, accurate and reproducible. 
However, miRNA detection currently falls short of most of these requisites. Biological variance, which 
has been largely neglected, represents an extremely important variable that affect the clinical utility of 
miRNAs as reliable markers. Currently there are no universally implemented guidelines for specimen 
collection, preparation and preservation. By using material from different sources obtained with 
dissimilar techniques, samples are more likely to show wide variability in profile. These are especially 
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pronounced when a highly sensitive technique like sequencing is used. Moreover, differences in 
specimen type can also introduce a profound effect on miRNA concentrations as well as expression 
levels. In addition to this pre-analytical variability, there are also variables specifically associated with 
miRNAs extraction and quantification methods. Often there is a low correlation of results obtained 
from different platforms, and sometimes even within the same platform, using reagents from different 
vendors. Data normalization, an often underestimated aspect of data processing, is another crucially 
important concern in obtaining accurate results. Hence baseline parameters such as pre-analytical, 
intra-individual, and inter-individual variability of miRNAs must be explored and defined. Steps must 
be taken to carefully select miRNA-profiling platforms and data analysis methods for the acquisition 
of clinically meaningful and dependable data. Furthermore, standardization of miRNAs extraction 
assays, quantification methods as well as miRNA biomarker evaluation is definitely needed. Finally 
and importantly, to date, most of the investigations into the use of miRNAs as biomarkers have been 
performed mainly in cell lines or animal models while other studies included only small cohorts of 
patient samples that were not validated in prospective clinical trials. A final decision for human use 
must be based on results derived from clinical trials with an adequate number of patient samples that 
represent a proof of concept for the field of miRNA as biomarkers. 
9. miRNAs as Potential Cancer Therapeutics 
The rationale for using miRNAs as anticancer drugs is based on the findings that miRNA 
expression is deregulated in cancer and that cancer phenotype can be changed by targeting miRNA 
expression. The evidenced deregulation of miRNAs in embryonal tumors [103,104] (Table 1) together 
with their association with the risk stratification and outcome prediction in these deadly cancers of 
childhood [103,104] (Tables 2 and 3), recommends miRNAs for targeting as novel therapeutic 
approaches and as effective treatment tools. Depending on expression levels and function of miRNAs, 
two approaches to develop miRNA-based therapies can be envisaged: antagonists (inhibition of 
oncogenic miRNAs) and mimetics (replacement of tumor suppressive miRNAs) [234]. Table 4 
illustrates preclinical analysis of diverse aberrantly expressed miRNAs in MB and NB that their 
therapeutic effects, which were determined with the tactics of reversing the expression level of these 
miRNAs in vitro and/or in vivo, have proven to be promising, reviewed in [102,235].  
Table 4. Example of preclinical functional studies of miRNAs in MB and NB [235].  
microRNAs Theraputic Potential Models Investigated Reference 
* miR124 
The adverse prognostic markers in MB (CDK6 SLC16A1D) 
are regulated by miR-124 
Overexpression of the tumor suppressor miR124 decreases MB 
cell growth in vitro and in xenograft tumors in mice suggesting 
possible use of miR-124 restoration in MB therapy 
D283, D341, D384, 
D425, D458,  
ONS-76 MB cell 
lines. D425 xenograft 
tumors in mice. 
[88,113] 
* miR199b-5p 
miR199b-5p target Notch effector HES1, which is involved in 
MB pathogenesis. miR199b-5p overexpression impairs the 
clonogenic potential of MB cell lines. Moreover MB tumor 
infection by adenovirus carrying miR199b-5p in a xenograft 
model reduces the tumor burden in vivo suggesting possible use 
of miR199b-5p as an adjuvant therapy 
Daoy cell line and 
Daoy xanograft 
mouse model. 
[109] 
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Table 4. Cont. 
microRNAs Theraputic Potential Models Investigated Reference 
* miR34a 
miR-34a is a regulator of the Notch ligand Dll1.  
Down-regulation of Dll1 expression by miR-34a negatively 
regulates cell proliferation, and induces apoptosis and neural 
differentiation in MB cells. In addition infection of 
adenoviruses carrying the precursor miR-34a induces 
neurogenesis, reduces tumor burden, and confers 
chemosensitivity in mice xenografts,  
Daoy cell line and 
Daoy xanograft 
mouse model. 
[236] 
* miR125b, 
miR324-5p, 
miR326 
miR125b, miR324-5p, miR326 suppress Hedgehog signaling 
which controls cerebellar granule cell progenitor (GCP) 
development as well as neoplastic transformation into MB. 
Overexpression of these miRNA increases GCP differentiation 
and inhibits MB cell proliferation, and colonies formation. 
Daoy and D283 cell 
lines. 
[27] 
* miR128a 
By targeting the Bmi-1 oncogene, miR-128a inhibits growth of 
MB cells and alters the intracellular redox state of the tumor 
cells and thereby promotes cellular senescence in MB cells. 
Daoy, ONS-76 cell 
lines. 
[118] 
* miR383 
Tumor suppressor miR-383 is down-regulated in MB. 
Overexpression of miR383 inhibits MB cell growth through 
targeting PRDX3 
Daoy, D283, D341, 
D384, D425, D458, 
ONS-76 cell lines. 
[237] 
* miR9, 
miR125a 
miR-9 and miR-125a are tumor suppressors that are 
downregulated in MB patient with poor survival. Rescued 
expression miR-9 and miR-125a promotes MB cell growth 
arrest and apoptosis by targeting truncated TrkC isoform or 
notch signal via His1.  
D283 and Daoy cell 
lines. 
D341, D425 
[107,111] 
* miR218 
miR-218 is significantly underexpressed in MB. miR-218 target 
multiple cancer associated genes such as REST, CDK6, 
RICTOR and CTSB in MB cells. Re-expression of miR-218 
resultes in a decrease in MB cell growth, colony formation, cell 
migration, invasion, and tumor sphere size. 
Daoy, D283, D341, 
D425, D458 and 
UW228 cell lines. 
[238] 
** miR-17-92 
Activation of miR-17-92 cluster is known as a marker for poor 
prognosis and poor survival of NB. miR-17-92 affect multiple 
cancer pathways including DKK3, CDKN1A, BIM, ER-α, 
MEF2D Its activation increases proliferation, decreases 
apoptosis and inhibits TGF-β signaling. Aggressive NB evade 
the cytostatic TGFβ-pathway through miR-17-92 directed 
targeting of the pathway. Reactivation of TGFβ-signaling 
through miR-17-92 inhibition could be a promising therapeutic 
approach for NB 
SHEP NB cell line 
xanograft mouse 
model. 
[131] 
** miR-21 
Oncogenic miR-21 promotes the proliferation and decreased 
sensitivity to chemotherapy of human NB cells. Ectopic 
expression of pre-miR-21 lower the level of tumor suppressor 
PTEN mRNA and protein and in NB cells. Transfection of anti-
miR-21 increases the PTEN expression. However, others 
reported that inhibition of miR-21 did not affect proliferation of 
NB cells, suggesting that the precise biological functions of 
miR-21 in NB still warrant further studies. 
SH-SY5Y and 
BE(2)-M17 NB cell 
lines 
[129] 
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Table 4. Cont. 
microRNAs Theraputic Potential Models investigated Reference 
** miR-380-5p 
miR-380 which is highly expressed in NB repress p53-
mediated apoptosis, and is associated with poor outcome in NB 
with MYCN amplification. miR-380 overexpression cooperates 
with activated HRAS oncoprotein and form tumors in mice. 
Inhibition of miR-380-5p in embryonic stem or NB cells results 
in induction of p53, and apoptotic cell death. In vivo delivery of 
a miR-380-5p antagonist decreases tumor size in NB orthotopic 
mouse model suggesting a promising potential therapeutic 
ability to miR-380 inhibitors 
TH-MYCN 
transgenic mice of 
NB 
Orthotopic NB 
model 
[132] 
** miR-15a 
miR-15a promotes the migration of NB cells through targeting 
the RECK-MMP-9 axis. Suppression of miR-15a decreases the 
migration and invasion whereas overexpression increases the 
migration ability of NB cell lines. These findings provide 
insights into the role of miR-15 in NB migration and invasion 
and qualify miR-15a as a potential therapeutic target. 
GI-LA-N and SK-N-
SH cell lines 
[133] 
** miR-34a 
Tumor suppressive miR-34 family members targets MYCN and 
inhibit the growth of NB cell lines In addition, other genes also 
targeted by miR-34a, including E2F3, BCL2, CCND1 and 
CDK4 were found to be involved in cell proliferation or 
apoptosis  
Over expression of miR-34a in NB cell lines induces cell cycle 
arrest decreases cell number and induces apoptosis. 
miR-34a significantly reduces tumor growth in an in vivo 
orthotopic murine model. 
Kelly, SK-N-AS cell 
lines NB1691luc NB 
cell lines 
NB xanograft mouse 
model 
[135] 
* Analysis in MB; ** Analysis in NB. Reviewed in [102,235]. 
9.1. miRNA Antagonists 
The most common strategy to ablate miRNA function is achieved by single-stranded oligonucleotides 
with miRNA complementary sequences (antisense). The backbones of these are chemically modified 
in order to increase the affinity towards the endogenous miRNA or, alternatively, to trigger the 
degradation of the endogenous miRNA. Examples of miRNA antagonists are anti-miRNA 
oligonucleotides (AMOs), locked-nucleic acids (LNA), miRNA sponges, miRNA masking and small 
molecule inhibitors specific for certain miRNAs [234,239,240]. The most widely used AMO are  
2¢-O-methyl AMOs, 2¢-O-methoxyethyl AMOs, and (LNA) AMOs [3,241–244]. miR-21 inhibition  
in vitro provides a good example of an anti-miR application in cancer cells. Knockdown of miR-21 
suppressed cell growth and activated apoptosis in cultured glioblastoma and breast cancer  
cells [12,161], reduced invasion in metastatic breast cancer, lung metastasis [245], colon cancer [99], 
glioblastoma [246] and MB culture cells [100]. 
In vivo studies also showed that treatment with LNA–anti-miR-21 oligonucleotides disrupted 
glioma growth [247]. Other studies have shown that intravenous administration of AMOs against  
miR-16, miR-122, miR-192 and miR-194 in animals offer efficient and sustained silencing of 
corresponding miRNAs [248]. As an alternative to chemically modified antisense oligos,  
vector-encoded RNA molecules, known as “miRNA sponges” have recently been designed to contain 
Molecules 2014, 19 5842 
 
 
multiple tandem binding sites to a miRNA of interest [249–251]. miRNA sponges function by 
immobilizing the target miRNAs and thus blocking their regulatory function in the cell. miRNA 
sponges are transcripts under the control of strong promoters (RNA polymerase II) and contain 
multiple tandem binding sites to a miRNA of interest. miRNA sponges are able to inhibit miRNA 
function as strongly as AMOs. In addition miRNA sponges have the advantage of being stably 
integrated into the genome, thus opening up the possibility of creating stable cell lines and transgenic 
animals that are functionally deficient for a specific miRNA family reviewed in [234,252,253]. 
However, the risk of insertional mutagenesis in target cells as well as challenges in the delivery of 
these non-small-molecules makes sponges not ideal for therapeutic applications. “miRNA masking” is 
another alternative strategy which refers to a sequence with perfect complementarity to the binding site 
of an endogenous miRNA in the target gene. This “miRNA masking” can form duplex with the target 
mRNA with higher affinity, therefore blocking the access of endogenous miRNA to its binding site 
without the potential side effects of mRNA degradation by AMOs [254]. 
The recent development of small molecules having the ability to modulate the function of miRNAs, 
renders miRNA pathways susceptible to small molecule inhibitors. Small molecule inhibitors have 
several advantages over traditional nucleic acid-based tools to manipulate miRNA function, since they 
are more easily delivered into humans or animals, they are intracellularly more stable, and they are less 
expensive to manufacture. Based on these promising developments, it can be expected that several new 
small molecule inhibitors of miRNA function will be discovered in the near future [254]. 
9.2. miRNA Replacement Therapy 
miRNA replacement therapy is the strategy of restoring tumor suppressive miRNAs which are lost 
in cancer cells, to re-establish their “normal” functions. In this regard miRNA mimics are either single 
or double-stranded miRNA that have the same sequence as the depleted, naturally occurring miRNA. 
As a consequence, miRNA replacement therapy is expected to have limited off-target effects. The 
simplicity, specificity and potency of mimicking miRNA precursors have made this an exciting 
approach to target genes for both research and therapeutic purposes [239]. 
Several technologies have proven effective in delivering therapeutic miRNAs to tumor tissues  
in vivo. These include adenoviral or lentiviral vector-based systems that were originally developed for 
gene therapy. A viral approach has been used to reintroduce Let-7 expression in an orthotopic lung 
cancer mouse model [255]. The reintroduction of Let-7 significantly reduced lung tumor formation  
in vivo [256]. In line with this is the reintroduction of miR-26a in a liver cancer mouse model, which 
resulted in the inhibition of cancer cell proliferation, induction of tumor-specific apoptosis, and 
prevention of disease progression [257]. Another example that shows the value of miRNA replacement 
is provided by miR-34a [258]. In this case, therapeutic delivery of miR-34a led to an accumulation of 
miR-34a in the tumor tissue, suppression of known miR-34a target genes and, most importantly, 
inhibition of lung tumor growth [240]. Similar to the replacement therapy approach but differing in 
miRNA delivery, unmodified miR-145 and miR-33a have been delivered by using polyethylenimine 
(PEI) in a mouse model of colon carcinoma, a method that proved efficacious [259]. Likewise 
transient transfection with synthetic miR-16 significantly reduced cell proliferation in prostate cancer 
cells in vitro and reduced metastasis in vivo [260]. Another example of the success of miRNA 
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replacement therapy is demonstrated by Garzia et al. [109]. The group showed that MB tumor burden 
can be reduced in a xenograft model by miR-199-5p overexpression, indicating the therapeutic 
potential of miR199b-5p. Also replacement for miR-15 and miR-16 [261], that are often deleted in 
CLL patients [261–263], reduces proliferation and triggers leukemic cell death, reviewed in [264]. 
Together, the evidence showing that miRNAs can function as tumor suppressors, and that the 
synthetic versions of these miRNAs robustly interfere with tumor growth, reflects the importance of 
miRNAs in cancer and strongly supports the development of miRNA mimics as ideal candidates for 
therapeutic intervention. 
9.3. Challenges of miRNA-based Therapies 
miRNAs biological instability, the difficulties of specific delivery, and the insufficient uptake for 
effective target inhibition challenge the development of miRNA-based therapies. To overcome these 
obstacles chemical modifications in oligonucleotides have been investigated, however the drawbacks 
of improved delivery to tissues after chemical modifications are impaired biological activity and 
increased toxicity. To solve these problems, novel miRNA formulations, including nanoparticles, 
polymers or viral transduction approaches, are currently under development. Moreover, effort is put 
into the engineering of effective systems that deliver synthetic miRNAs selectively to diseased tissues 
in order to limit potentially toxic off-target effects, reviewed in [265]. Finally and importantly 
homeostasis of the brain is dependent on the blood-brain barrier (BBB) that dictates the exchange of 
essential nutrients and limits the entrance of molecules and immune cells into the central nervous 
system. This barrier therefore forms yet another important hurdle for effective miRNAs treatment of 
malignant brain cancer. Hence effective brain delivery for miRNAs may require the design of 
particular therapeutic approaches that overcome this physiological obstruction, such as the use of 
nanoparticles, immunoliposomes, peptide vectors or carrier-mediated transport through the BBB, 
reviewed in [266]. 
In summary, the recent fast progress in the field has triggered some optimism about the 
development of successful molecules targeting microRNAs. However miRNAs targeting approaches 
are still at the preclinical stage and even with promising preclinical responses to molecules targeting 
miRNAs or their target genes, it is expected that tumor types and context will add to the complexity 
and heterogeneity of response to any of the above mentioned strategies. New therapies targeting 
miRNAs or its’ target genes may best be applied in the future together with molecular profiling of 
cancers for clinical stratification and selection of combination therapies. 
10. Concluding Remarks 
Within the last decade, substantial progress has been made in understanding embryonal tumor 
development through the discovery of deregulations in the highly conserved developmental signaling 
pathways. However, effective targeted therapies still remain elusive and the development of novel 
therapeutic strategies remains an urgent goal. Risk stratification and drug-response prediction are the 
central elements of targeted therapies. During recent years, research has focused mainly on gene 
expression profiling in embryonal tumors and a number of important studies have been published. As 
gene expression profiling reaches a plateau and begins to face limitations, miRNA signature is a rising 
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star that may provide new resolutions to old problems. Numerous miRNAs are dysregulated in 
pediatric cancers, and evidence suggests miRNAs as attractive targets in cancer therapy. A greater 
understanding of miRNA biology and the development of suitable delivery systems are required to 
translate basic research results into clinical practice. miRNAs are much more stable in body fluids than 
mRNAs, raising the exciting prospect that miRNAs might be used as non-invasive biomarkers for 
disease monitoring and risk stratification under specific circumstances. Insights gained from miRNA 
studies may open a new era in pediatric brain cancer treatments which provides improved patient 
selection for targeted agents, and forms the basis for the development of novel therapeutics and/or 
early disease biomarkers. 
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